LXRX Lexicon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LXRX

Price (delayed)

$1.61

Market cap

$396.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.8

Enterprise value

$478.75M

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes ...

Highlights
LXRX's revenue has soared by 127% from the previous quarter
The company's gross profit has surged by 117% QoQ
LXRX's debt has surged by 94% year-on-year
The net income has plunged by 74% YoY and by 12% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lexpharma.com
Peers: REGN RARE ILMN ESPR

Key stats

What are the main financial stats of LXRX
Market
Shares outstanding
246.24M
Market cap
$396.44M
Enterprise value
$478.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.24
Price to sales (P/S)
295.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
397.63
Earnings
Revenue
$1.2M
EBIT
-$164.02M
EBITDA
-$163.46M
Free cash flow
-$162.37M
Per share
EPS
-$0.8
Free cash flow per share
-$0.73
Book value per share
$0.38
Revenue per share
$0.01
TBVPS
$0.84
Balance sheet
Total assets
$229.43M
Total liabilities
$136.32M
Debt
$104.77M
Equity
$93.11M
Working capital
$145M
Liquidity
Debt to equity
1.13
Current ratio
5.6
Quick ratio
5.42
Net debt/EBITDA
-0.5
Margins
EBITDA margin
-13,576.7%
Gross margin
92.9%
Net margin
-14,710.9%
Operating margin
-14,265%
Efficiency
Return on assets
-71.9%
Return on equity
-139.7%
Return on invested capital
-73.5%
Return on capital employed
-82.9%
Return on sales
-13,622.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LXRX stock price

How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
-5.85%
1 week
-5.01%
1 month
-28.76%
1 year
-35.34%
YTD
5.23%
QTD
-32.92%

Financial performance

How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$1.2M
Gross profit
$1.12M
Operating income
-$171.75M
Net income
-$177.12M
Gross margin
92.9%
Net margin
-14,710.9%
LXRX's revenue has soared by 127% from the previous quarter
The company's gross profit has surged by 117% QoQ
LXRX's net margin has surged by 80% year-on-year and by 51% since the previous quarter
LXRX's operating margin has surged by 80% year-on-year and by 51% since the previous quarter

Growth

What is Lexicon Pharmaceuticals's growth rate over time

Valuation

What is Lexicon Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.24
P/S
295.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
397.63
The company's EPS fell by 29% YoY and by 3.9% QoQ
Lexicon Pharmaceuticals's equity has decreased by 33% QoQ and by 21% YoY
The P/B is 25% higher than the last 4 quarters average of 3.4 and 18% higher than the 5-year quarterly average of 3.6
LXRX's revenue has soared by 127% from the previous quarter
LXRX's price to sales (P/S) is 79% less than its last 4 quarters average of 1394.6 and 69% less than its 5-year quarterly average of 965.4

Efficiency

How efficient is Lexicon Pharmaceuticals business performance
The company's return on sales has surged by 81% YoY and by 51% QoQ
The company's return on equity fell by 46% YoY and by 17% QoQ
LXRX's ROIC is up by 34% YoY and by 2.4% from the previous quarter
LXRX's ROA is down by 12% YoY and by 8% QoQ

Dividends

What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LXRX.

Financial health

How did Lexicon Pharmaceuticals financials performed over time
The total assets is 68% greater than the total liabilities
LXRX's total liabilities has surged by 77% year-on-year
Lexicon Pharmaceuticals's quick ratio has decreased by 20% from the previous quarter and by 9% YoY
LXRX's debt is 13% greater than its equity
Lexicon Pharmaceuticals's debt to equity has surged by 146% YoY and by 51% QoQ
LXRX's debt has surged by 94% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.